Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2022 | $4.00 | Mkt Perform | Barrington Research |
| 3/24/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 8/20/2021 | $3.50 | Neutral → Buy | DA Davidson |
| 8/19/2021 | Neutral → Buy | DA Davidson | |
| 8/12/2021 | $3.50 → $3.75 | Neutral → Buy | Ladenburg Thalmann |
Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde
First quarter 2024 total revenues of $13.2 million, up 30% from first quarter 2023First quarter 2024 net income of $309 thousand, or diluted earnings per share of $0.01, versus net loss of $160 thousand, or diluted earnings per share of $(0.00) for first quarter 2023First quarter 2024 Adjusted EBITDA of $1.7 million, up 135% from $720 thousand for first quarter 2023, while diluted Adjusted EBITDA per share was $0.03 versus $0.01 for first quarter 20231Total plasma center count increased by five net new centers during first quarter 2024, exiting the quarter with 469 centers, contributing to an 11% increase in plasma revenue versus the same period last yearAdded 10 net new patient affordabilit
For the Full YearFull-year 2023 total revenues of $47.3 million, up 24% from full-year 2022Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share of $0.02 for full-year 2022Full-year 2023 Adjusted EBITDA of $6.7 million, up 21% from $5.5 million a year ago, while diluted Adjusted EBITDA per share was $0.12 versus $0.10 for full-year 20221Total plasma center count increased by 20 during 2023, exiting the year with 464 centers, contributing to a 21% increase in plasma revenue versus the same period last yearLaunched 24 net new patient affordability programs during 2023, exiting the year with 43 active
S-8 - Paysign, Inc. (0001496443) (Filer)
S-8 POS - Paysign, Inc. (0001496443) (Filer)
S-8 - Paysign, Inc. (0001496443) (Filer)
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss its third quarter 2024 financial results at 5:00 p.m. Eastern time on Tuesday, November 5, 2024. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13749532 The replay will be available until February 5, 2025. To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. Eastern time on Frida
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing, today announced their participation in the Sidoti Micro-Cap Virtual Conference, taking place August 14-15, 2024. Jeff Baker, Paysign's Chief Financial Officer, will be available for one-on-one and small group meetings with investors during the event. Paysign is scheduled for a group presentation on Wednesday, August 14, at 4:00 p.m. EDT. To register or learn more about the conference, investors may visit the event website or visit the webinar registration page to attend the live group presentation. Forwar
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced they will be presenting at the Oppenheimer 27th Annual Technology, Internet & Communications Conference to be held August 12-14, 2024, through a virtual format. The focus of the virtual conference is to provide an expansive look across the dynamic sector of the world economy at existing and emerging technologies and provide potential investors the opportunity to evaluate public companies at the forefront of these technological innovations. Paysign's Chief Financial Officer, Jeff Baker, is sch
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
PaySign (NASDAQ:PAYS) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 3 0 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.07, along with a high estimate of $7.00 and a low estimate of $4.50. This current average has increased by 8.98%
Barrington Research analyst Gary Prestopino maintains PaySign (NASDAQ:PAYS) with a Outperform and maintains $7 price target.
In the last three months, 9 analysts have published ratings on PaySign (NASDAQ:PAYS), offering a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 5 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 2 0 0 0 Analysts have set 12-month price targets for PaySign, revealing an average target of $5.61, a high estimate of $7.00, and a low estimate of $4.00. This current average reflects an increase of 10.87% from
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Ladenburg Thalmann downgraded PaySign from Buy to Neutral
DA Davidson upgraded PaySign from Neutral to Buy and set a new price target of $3.50
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)